Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ProdiGene/USDA settlement

Executive Summary

ProdiGene and Department of Agriculture reach settlement that includes a $250,000 fine and a commitment to additional inspections and employee training after ProdiGene's pharmaceutical-producing corn commingled with soybean crops (1"The Pink Sheet" Nov. 25, p. 24)...

You may also be interested in...



ProdiGene To Develop “Field Trial” Compliance Program Following Violation

ProdiGene is working with FDA and USDA to develop a compliance program as part of a settlement agreement relating to safety violations in the production of plant-made pharmaceuticals

The Top Five (Non-COVID) Pharma Stories Of 2020

The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.

The Race To Vaccinate The World Against COVID-19

Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel